Format

Send to

Choose Destination
Rheumatology (Oxford). 2017 May 1;56(5):818-828. doi: 10.1093/rheumatology/kew492.

Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings.

Author information

1
Policlinic of Rheumatology, Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany.
2
Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy.
3
Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Ourense y Pontevedra, Spain.
4
Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Solna, Sweden.
5
HEOR, Real-World Evidence Solutions (RWES) unit, IMS Health, Paris-La Défense, France.
6
Global Specialty Pharma Franchise, GlaxoSmithKline; Services Unlimited, Brentford, UK.
7
Immunology Medical Department, GlaxoSmithKline spa, Verona, Italy.
8
Department of Internal Medicine and Systemic Diseases, University Hospital of Dijon, 5bis INSERM U866 5ter INSERM CIC-EC 1432, Dijon, France.

Abstract

Objectives:

The aim was to evaluate the cross-cultural validity of the Lupus Impact Tracker (LIT) in five European countries and to assess its acceptability and feasibility from the patient and physician perspectives.

Methods:

A prospective, observational, cross-sectional and multicentre validation study was conducted in clinical settings. Before the visit, patients completed LIT, Short Form 36 (SF-36) and care satisfaction questionnaires. During the visit, physicians assessed disease activity [Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI], organ damage [SLICC/ACR damage index (SDI)] and flare occurrence. Cross-cultural validity was assessed using the Differential Item Functioning method.

Results:

Five hundred and sixty-nine SLE patients were included by 25 specialists; 91.7% were outpatients and 89.9% female, with mean age 43.5 (13.0) years. Disease profile was as follows: 18.3% experienced flares; mean SELENA-SLEDAI score 3.4 (4.5); mean SDI score 0.8 (1.4); and SF-36 mean physical and mental component summary scores: physical component summary 42.8 (10.8) and mental component summary 43.0 (12.3). Mean LIT score was 34.2 (22.3) (median: 32.5), indicating that lupus moderately impacted patients' daily life. A cultural Differential Item Functioning of negligible magnitude was detected across countries (pseudo- R 2 difference of 0.01-0.04). Differences were observed between LIT scores and Physician Global Assessment, SELENA-SLEDAI, SDI scores = 0 (P < 0.035) and absence of flares (P = 0.004). The LIT showed a strong association with SF-36 physical and social role functioning, vitality, bodily pain and mental health (P < 0.001). The LIT was well accepted by patients and physicians. It was reliable, with Cronbach α coefficients ranging from 0.89 to 0.92 among countries.

Conclusion:

The LIT is validated in the five participating European countries. The results show its reliability and cultural invariability across countries. They suggest that LIT can be used in routine clinical practice to evaluate and follow patient-reported outcomes in order to improve patient-physician interaction.

KEYWORDS:

Lupus Impact Tracker; cross-cultural validation; differential item functioning/Rasch method; patient-reported outcome tool; systemic lupus erythematosus

PMID:
28204765
DOI:
10.1093/rheumatology/kew492
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center